Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Cytokine Release Syndrome 1

Interventions

pembrolizumab 20Cisplatin 14Carboplatin 13Paclitaxel 12Radiation 11Doxorubicin 10Radiotherapy 9Nivolumab 9Cyclophosphamide 9Cytarabine 8Vincristine 7Radiotherapy, Intensity-Modulated 7Metformin 7Magnetic Resonance Spectroscopy 7Etoposide 7Leucovorin 6Ipilimumab 6Injections 6Fluorouracil 6Docetaxel 6tislelizumab 5Specimen Handling 5Radiotherapy, Conformal 5Prednisone 5Pemetrexed 5Methotrexate 5Cetuximab 5Bevacizumab 5fludarabine 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × siltuximab × 30 days × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡